167 related articles for article (PubMed ID: 35802834)
1. Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.
Soumerai JD; Rosenthal A; Harkins S; Duffy J; Mecca C; Wang Y; Grewal RK; El-Jawahri AR; Liu H; Menard C; Dogan A; Yang L; Rimsza LM; Bantilan K; Martin H; Lei M; Mohr S; Kurilovich A; Kudryashova O; Postovalova E; Nardi V; Abramson JS; Chiarle R; Zelenetz AD; Louissaint A
Blood; 2022 Oct; 140(16):1822-1826. PubMed ID: 35802834
[No Abstract] [Full Text] [Related]
2. Anaplastic Lymphoma Kinase (ALK) Positive Neuroendocrine Tumor of Lung With Favorable Response to Alectinib (ALK Inhibitor).
Ghimire B; Pokharel A; Karki U; Thapa S; Chisti MM
Clin Lung Cancer; 2023 May; 24(3):e113-e116. PubMed ID: 36690569
[No Abstract] [Full Text] [Related]
3. Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
Christopoulos P; Bozorgmehr F; Brückner L; Chung I; Krisam J; Schneider MA; Stenzinger A; Eickhoff R; Mueller DW; Thomas M
BMC Cancer; 2021 Jun; 21(1):743. PubMed ID: 34182952
[TBL] [Abstract][Full Text] [Related]
4. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Golding B; Luu A; Jones R; Viloria-Petit AM
Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
[TBL] [Abstract][Full Text] [Related]
5. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
6. Research Progress on the Drug Resistance of ALK Kinase Inhibitors.
Li Z; Liu F; Wu S; Ding S; Chen Y; Liu J
Curr Med Chem; 2022; 29(14):2456-2475. PubMed ID: 34365942
[TBL] [Abstract][Full Text] [Related]
7. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
8. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
9. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Takahashi K; Seto Y; Okada K; Uematsu S; Uchibori K; Tsukahara M; Oh-Hara T; Fujita N; Yanagitani N; Nishio M; Okubo K; Katayama R
Thorac Cancer; 2020 Mar; 11(3):581-587. PubMed ID: 31943796
[TBL] [Abstract][Full Text] [Related]
10. Durable responses with ALK inhibitors for primary refractory anaplastic lymphoma Kinase-positive large B-cell lymphoma.
Takiar R; Phillips TJ
Blood Adv; 2023 Jun; 7(12):2912-2916. PubMed ID: 36812691
[No Abstract] [Full Text] [Related]
11. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Dagogo-Jack I; Yoda S; Lennerz JK; Langenbucher A; Lin JJ; Rooney MM; Prutisto-Chang K; Oh A; Adams NA; Yeap BY; Chin E; Do A; Marble HD; Stevens SE; Digumarthy SR; Saxena A; Nagy RJ; Benes CH; Azzoli CG; Lawrence MS; Gainor JF; Shaw AT; Hata AN
Clin Cancer Res; 2020 Jun; 26(11):2535-2545. PubMed ID: 32086345
[TBL] [Abstract][Full Text] [Related]
12. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
[TBL] [Abstract][Full Text] [Related]
13. Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance.
Xu H; Yang G; Yang L; Yang Y; Ma D; Li J; Hao X; Xing P; Wang Y
Thorac Cancer; 2019 May; 10(5):1096-1102. PubMed ID: 30920172
[TBL] [Abstract][Full Text] [Related]
14. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
15. Alectinib in first-line treatment for advanced anaplastic lymphoma kinase mutation-positive (alk+) non-small cell lung cancer (NSCLC): a cost-effective change.
Giuliani J; Bonetti A
Recenti Prog Med; 2021 Jun; 112(6):472-475. PubMed ID: 34128941
[No Abstract] [Full Text] [Related]
16. Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine.
Remon J; Tabbò F; Jimenez B; Collazo A; de Castro J; Novello S
Clin Transl Oncol; 2020 Sep; 22(9):1425-1429. PubMed ID: 31955355
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors.
Doi Y; Tagaya H; Noge A; Semba K
Target Oncol; 2022 Nov; 17(6):695-707. PubMed ID: 36201110
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Molecular Evolution of an
Gene-Olaciregui N; Perez-Somarriba M; Santa-María V; Cruz O; Gómez-González S; Castañeda A; Suñol M; Rovira C; Muchart J; Hinojosa J; La Madrid AM; Lavarino C
JCO Precis Oncol; 2023 Mar; 7():e2200547. PubMed ID: 36996378
[No Abstract] [Full Text] [Related]
19. PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
Li T; Zhang F; Wu Z; Cui L; Zhao X; Wang J; Hu Y
Lung Cancer; 2020 Jan; 139():146-150. PubMed ID: 31794921
[TBL] [Abstract][Full Text] [Related]
20. Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement.
Rigaud C; Abbou S; Ducassou S; Simonin M; Le Mouel L; Pereira V; Gourdon S; Lambilliotte A; Geoerger B; Minard-Colin V; Brugieres L
Haematologica; 2022 Sep; 107(9):2255-2260. PubMed ID: 35586965
[No Abstract] [Full Text] [Related]
[Next] [New Search]
